Clinical Trial Update: Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update for ARO-ANG3 in participants with Homozygous Familial Hypercholesterolemia, currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Homozygous Familial Hypercholesterolemia

Drugs mentioned

• ARO-ANG3

Snippet

Sponsor: Arrowhead Pharmaceuticals | Conditions: Homozygous Familial Hypercholesterolemia | Phase 2 | Status: ACTIVE_NOT_RECRUITING